SAN DIEGO, CA - January 29, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a developer of blood purification technologies to treat life-threatening conditions, today announced the appointment of Michael Ryan to its Board of Directors.
Mr. Ryan is a seasoned executive, entrepreneur and investor within the early-stage technology and life science industry. Mr. Ryan is a Founding Director of Irrus Investments, Ltd., a role he has held since 2011. Irrus Investments is the largest angel investment syndicate in Ireland with an emphasis on life science companies. To date, Irrus has invested over $50 million in 40 early-stage life science and technology companies in Ireland, UK, Sweden and the United States.
Mike brings a wealth of medical technology industry experience and investment expertise to our Board,” stated Sigyn Therapeutics CEO, Jim Joyce. “He is a valued supporter of our endeavors, whose contributions as a board member will help us achieve our mission to develop blood purification technologies that save lives.”
Mr. Ryan previously served as Chief Executive Officer and Board Member of Sedana Medical, from 2011 until shortly before the Company launched on the Nasdaq owned First North stock exchange in Stockholm in 2017. Prior to this, he was the main shareholder and Chief Executive Officer of Artema Medical AB, where he helped orchestrate the Company’s acquisition by Datascope Corporation. Mr. Ryan holds a B.Eng in Mechanical Engineering and a Masters in Industrial Engineering from University College Dublin.
“I am excited to join the Sigyn Therapeutics Board of Directors,” stated Mr. Ryan. “The Company has established a compelling clinical and commercialization strategy to advance Sigyn Therapy, whose expansive capabilities introduce a strategy to treat infectious disease disorders that are significant global health challenges.”
About Sigyn Therapeutics™
Sigyn Therapeutics is developing blood purification technologies to enhance the benefit of cancer therapies and to address life-threatening infections that are not treatable with drugs. The Company’s lead product candidate, Sigyn TherapyTM has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn TherapyTM is a candidate to treat life-threatening viruses, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals. The clinical protocol of first-in-human studies incorporates Sigyn Therapy in series with regularly schedule dialysis treatments to address endotoxemia and concurrent inflammation, which contribute to shortening the lives of end-stage renal disease (ESRD) patients. Extending the lives of individuals with ESRD would boost dialysis industry revenues.
The Company has also established an oncology pipeline comprised of ImmunePrepTM, a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrepTM to improve the delivery of chemotherapeutic agents; and ChemoPureTM to reduce chemotherapy toxicity. If successfully advanced, the Company’s therapies offer to provide strategic value to the dialysis and biopharmaceutical industry.
To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com
Cautionary Note Regarding Forward-Looking Statements
This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Contacts:
Johan Louw
Senior Vice President of Strategic Programs
281.660.1815
jlouw@SigynTherapeutics.com
Jim Joyce
Chairman, CEO
Email: jj@SigynTherapeutics.com
